Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 266 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Respiratory Distress Syndrome
Interventions
Tenecteplase
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Macon, Georgia
Conditions
Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
0 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Conditions
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Atibuclimab, Placebo
Biological · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Seattle, Washington
Conditions
ARDS (Acute Respiratory Distress Syndrome), VV ECMO
Interventions
Mechanical Power Targeted Ventilation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Conditions
Lung Injury, Acute
Interventions
SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 3 more
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
V/Q System
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
ARDS, Critical Illness, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Default order set, Physician-targeted accountable justification, Respiratory therapist (RT)-targeted accountable justification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 99 Years
Enrollment
7,342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Plainsboro, New Jersey • Philadelphia, Pennsylvania • West Chester, Pennsylvania
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort C: bevacizumab, Cohort C: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Not listed No phase listed Observational Accepts healthy volunteers

Postoperative Respiratory Abnormalities

NCT04079829
Conditions
Respiratory Failure, Respiratory Arrest, Respiratory Distress Syndrome, Acute Respiratory Failure, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure With Hypercapnia, Acute Respiratory Failure Post Surgical, Acute Respiratory Failure Postprocedural, Acute Respiratory Failure Following Trauma and Surgery, Acute Respiratory Failure Requiring Reintubation, Acute Respiratory Failure Post Traumatic, Acute Respiratory Decompensation, Shock, Shock, Septic, Shock, Cardiogenic, Acute Cardiac Failure, Multi Organ Failure, Acute Kidney Failure
Interventions
Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
Other
Lead sponsor
Efficacy Care R&D Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 2 Interventional Results available

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

NCT04365257
Conditions
COVID-19
Interventions
Prazosin, Standard of care
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Respiratory Distress Syndrome
Interventions
ASV, Lung Protective Ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Acute Respiratory Distress Syndrome
Interventions
Ventilator settings
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Xigris
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • San Francisco, California + 5 more
Conditions
SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo
Drug · Device
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 10 more
Completed No phase listed Observational

Identifying PARDS Endotypes

NCT03539783
Conditions
Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions
Respiratory epithelial cell brushing
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 18 Years
Enrollment
76 participants
Timeline
2018 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Early Insulin and Development of ARDS

NCT00605696
Conditions
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Brexanolone, Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more
Conditions
COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Lucinactant
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • Augusta, Georgia + 3 more
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more